Key result
Propofol-supplemented cardioplegia yielded uncertain effects on post-operative troponin levels compared to standard cardioplegia.
Why the study?
To determine the probability of a clinically relevant reduction in post-operative myocardial injury following the use of propofol-supplemented cardioplegia.
Does propofol-supplemented cardioplegic solution reduce post-operative troponin levels in adult patients undergoing cardiac surgery requiring cardiopulmonary bypass?
Meta-Analysis (n=523)
Does propofol-supplemented cardioplegic solution reduce post-operative troponin levels in adult patients undergoing cardiac surgery requiring cardiopulmonary bypass?
Answers are grounded in this paper and cite their sources.
There is no convincing evidence to support the routine addition of propofol to standardized cardioplegic protocols for myocardial protection during cardiac surgery.
Objectives To determine the probability of a clinically relevant reduction in post-operative myocardial injury following the use of propofol-supplemented cardioplegia. Design Systematic review and Bayesian meta-analysis. Setting Perioperative cardiac surgery. Participants Adult patients (n=523) undergoing cardiac surgery requiring cardiopulmonary bypass. Interventions Propofol-supplemented cardioplegic solution versus standard cardioplegia. Measurements and Main results The primary endpoint was post-operative troponin levels. A Bayesian hierarchical random-effects model using weakly informative priors yielded a pooled standardized mean difference (SMD) of -0.05 (95% credible interval [CrI], -0.33 to 0.24). The posterior probability of any reduction in post-operative troponin levels (SMD < 0) was 70.8%. Secondary endpoints showed similarly uncertain evidence of benefit, including postoperative creatinine levels (SMD -0.06; 95% CrI, -0.71 to 0.46; probability of benefit, 59.8%), serious complications (risk ratio [RR], 0.77; 95% CrI, 0.18 to 2.28; probability of benefit, 70.3%), and postoperative arrhythmias (RR, 0.96; 95% CrI, 0.51 to 1.62; probability of benefit, 56.4%). Conclusions Current evidence suggests moderate posterior probabilities of benefit across endpoints. However, substantial uncertainty remains regarding the magnitude and direction of the true treatment effects. These findings do not provide convincing evidence to support routine addition of propofol to standardized cardioplegic protocols and should remain at the discretion of the heart surgery team.
No takes yet. Share an insight, caveat, or question.
Esparza et al. (2026) conducted a meta-analysis in Cardiac surgery requiring cardiopulmonary bypass (n=523). Propofol-supplemented cardioplegic solution vs. Standard cardioplegia was evaluated on Post-operative troponin levels (SMD -0.05, 95% CI -0.33 to 0.24). Propofol-supplemented cardioplegia yielded uncertain effects on post-operative troponin levels compared to standard cardioplegia.
Synapse has enriched 10 related papers. Consider them for comparative context: